Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metyrapone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Esteve Healthcare
Deal Size : $294.2 million
Deal Type : Divestment
Perrigo Receives Offer To Divest HRA Pharma Rare Diseases Business
Details : Esteve expands its rare disease portfolio through divestment, including Metopirone (metyrapone) for treating symptoms of Cushing's syndrome by lowering cortisol levels.
Product Name : Metopirone
Product Type : Steroid
Upfront Cash : $203.3 million
April 25, 2024
Lead Product(s) : Metyrapone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Esteve Healthcare
Deal Size : $294.2 million
Deal Type : Divestment
Lead Product(s) : Metyrapone,Oxazepam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The randomized, double-blind, placebo-controlled Phase 2 clinical trial is supported by funding from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health and will evaluate EMB-001 as a treatment option for patients with cocain...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Metyrapone,Oxazepam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metyrapone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
April 02, 2015
Lead Product(s) : Metyrapone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metyrapone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 21, 2014
Lead Product(s) : Metyrapone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable